TipRanks
Advertisement
Advertisement

DE:TCE2 Stock Latest News

Celldex adverse event concerns overblown, says H.C. Wainwright
The FlyCelldex adverse event concerns overblown, says H.C. Wainwright
1d ago
CLDX
Celldex price target raised to $88 from $70 at Leerink
PremiumThe Fly
Celldex price target raised to $88 from $70 at Leerink
10d ago
CLDX
Celldex price target raised to $57 from $50 at Morgan Stanley
PremiumThe Fly
Celldex price target raised to $57 from $50 at Morgan Stanley
10d ago
CLDX
Celldex falls -11.4%
PremiumThe Fly
Celldex falls -11.4%
11d ago
CLDX
Midday Fly By: AutoZone reports Q4 beat, Binance invests in Circle Internet
PremiumThe Fly
Midday Fly By: AutoZone reports Q4 beat, Binance invests in Circle Internet
11d ago
GS
KR
Celldex price target raised to $64 from $42 at H.C. Wainwright
PremiumThe FlyCelldex price target raised to $64 from $42 at H.C. Wainwright
11d ago
CLDX
Celldex falls -5.1%
Premium
The Fly
Celldex falls -5.1%
11d ago
CLDX
Celldex reports strong Phase 3 data in urticaria
Premium
Company Announcements
Celldex reports strong Phase 3 data in urticaria
11d ago
8K
CLDX
Celldex’s barzolvolimab meets endpoints in Phase 3 urticaria trial
PremiumThe Fly
Celldex’s barzolvolimab meets endpoints in Phase 3 urticaria trial
11d ago
CLDX
Barzolvolimab’s Strong CSU Prospects Lead Sam Slutsky to Reaffirm Buy on CLDX with Unchanged $56 Price Target
PremiumRatings
Barzolvolimab’s Strong CSU Prospects Lead Sam Slutsky to Reaffirm Buy on CLDX with Unchanged $56 Price Target
13d ago
CLDX
Celldex price target raised to $50 from $46 at Morgan Stanley
PremiumThe Fly
Celldex price target raised to $50 from $46 at Morgan Stanley
23d ago
CLDX
Celldex: Buy Rating Reaffirmed as Strong 2Q26 Results, Robust Pipeline Support Unchanged $60 Price Target
PremiumRatings
Celldex: Buy Rating Reaffirmed as Strong 2Q26 Results, Robust Pipeline Support Unchanged $60 Price Target
2M ago
CLDX
Barzolvolimab’s Accelerated CSU Progress and Robust Market Backdrop Underpin Maintained Buy Rating and Unchanged $56 Price Target
PremiumRatingsBarzolvolimab’s Accelerated CSU Progress and Robust Market Backdrop Underpin Maintained Buy Rating and Unchanged $56 Price Target
2M ago
CLDX
Celldex price target raised to $46 from $40 at Morgan Stanley
Premium
The Fly
Celldex price target raised to $46 from $40 at Morgan Stanley
2M ago
CLDX
Celldex: Barzo Franchise Momentum and Upcoming Catalysts Support Buy Rating with Unchanged $42 Price Target
Premium
Ratings
Celldex: Barzo Franchise Momentum and Upcoming Catalysts Support Buy Rating with Unchanged $42 Price Target
2M ago
CLDX
Celldex price target raised to $53 from $48 at Barclays
PremiumThe Fly
Celldex price target raised to $53 from $48 at Barclays
2M ago
CLDX
Celldex reports Q2 EPS (94c), consensus ($1.06)
PremiumThe Fly
Celldex reports Q2 EPS (94c), consensus ($1.06)
2M ago
CLDX
Celldex Therapeutics (CLDX) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Celldex Therapeutics (CLDX) Q2 Earnings Cheat Sheet
2M ago
CLDX
Celldex price target raised to $72 from $48 at Wells Fargo
PremiumThe Fly
Celldex price target raised to $72 from $48 at Wells Fargo
2M ago
CLDX
Celldex price target lowered to $61 from $67 at Cantor Fitzgerald
PremiumThe FlyCelldex price target lowered to $61 from $67 at Cantor Fitzgerald
2M ago
CLDX
Celldex price target lowered to $48 from $54 at Wells Fargo
Premium
The Fly
Celldex price target lowered to $48 from $54 at Wells Fargo
2M ago
CLDX
Celldex price target lowered to $40 from $44 at Morgan Stanley
Premium
The Fly
Celldex price target lowered to $40 from $44 at Morgan Stanley
2M ago
CLDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >